Core Viewpoint - The company has established multiple special accounts for fundraising and has undergone changes in the management and usage of these funds, ensuring compliance with regulatory requirements and optimizing the use of idle funds for cash management and project financing [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Fundraising and Account Management - On June 30, 2020, the company signed a five-party supervision agreement for special fundraising accounts with its subsidiaries and banks, establishing accounts at Guangfa Bank and China Construction Bank [1]. - The company has made several changes to its special fundraising accounts, including the establishment of new accounts and the cancellation of old ones, ensuring that all funds are properly managed and transferred [2][3]. - As of September 30, 2025, the company reported a total of RMB 64,276.06 million in invested fundraising, with RMB 8,000.00 million in idle funds managed for cash management purposes [12][17]. Fund Usage and Project Changes - The company has utilized its fundraising for various projects, with specific changes in project funding allocations to optimize resource use and enhance project efficiency [5][6][18][24][25][26]. - The company has received government subsidies totaling approximately RMB 49.89 million, which have contributed to reducing project costs and improving fundraising efficiency [6]. - The company has made adjustments to its project focus, shifting resources towards HIV-related drug development and other strategic areas, while slowing down projects in the oncology sector due to increased competition and resource constraints [24][26][27][28]. Economic Benefits and Performance - The company has reported significant sales revenues from its new drug projects, with sales of RMB 4,884.38 million, RMB 13,354.27 million, and RMB 18,516.06 million for the years 2023, 2024, and the first nine months of 2025, respectively [32]. - The raw material production and research project has achieved a financial internal rate of return of 27.73% and a payback period of 6.50 years, indicating strong economic viability [34]. - The company has successfully completed several clinical projects, with ongoing research expected to yield further economic benefits in the future [18][32][34].